Group 1 - The stock price of Aimeike is reported at 181.89 yuan, down 0.37% from the previous trading day, with a trading range of 179.05 yuan to 182.56 yuan and a transaction amount of 772 million yuan [1] - Aimeike is a leading company in the field of biological medical soft tissue repair materials in China, focusing on the research, production, and sales of medical beauty-related products, including injectable sodium hyaluronate series and polycaprolactone facial implant lines [1] - The company recently announced on its investor interaction platform that its semaglutide injection is indicated for weight management, and the project is currently progressing normally [1] Group 2 - Aimeike is acquiring the South Korean company REGEN to introduce advanced overseas technology and accelerate product iteration and upgrades [1] - Aimeike's subsidiary, REGEN, is involved in an arbitration case amounting to 1.6 billion yuan, which has not yet been heard in court [1] - Data shows that Aimeike experienced a net outflow of 120 million yuan in main funds on the day, with a cumulative net outflow of 245 million yuan over the past five days [1]

Core Viewpoint - The article highlights the recent C-round financing of Puriyan Medical Technology Co., Ltd., amounting to nearly $50 million, aimed at enhancing its product development and market expansion in the aesthetic medical field [1]. Company Overview - Puriyan was established in May 2018 and is headquartered in Nanjing, focusing on medical polymer materials and biological tissue engineering [3]. - The company adopts a serious medical approach to product development, establishing key technology platforms for the engineering preparation of polylactic acid microspheres and decellularized matrix particles [3][5]. Main Business - Puriyan's primary business includes the R&D and production of medical polymer materials and biological tissue engineering products, with a focus on Class I medical devices and expansion into Class II medical devices and aesthetic products [4]. - The company has successfully launched self-developed products such as polylactic acid facial fillers and recombinant collagen series products, with its "童颜针" being the first domestically produced polylactic acid facial filler using a fully sterile filling process [4]. Technology Platforms - Puriyan has established two key technology platforms that address challenges in the underlying materials and processes of medical devices, having obtained two NMPA Class III registration certificates [5]. - The company operates a production facility of over 4,000 square meters and a cleanroom of over 1,000 square meters, equipped with fully automated production and inspection equipment, ensuring high production quality [5].